IL-1 Receptor Inhibitor for Granulomatous Complications in Patients With Chronic Granulomatous Disease

NCT04136028 · clinicaltrials.gov ↗

EARLY_PHASE1

Phase

COMPLETED

Status

13

Enrollment

OTHER

Sponsor class

Conditions

Chronic Granulomatous Disease

Interventions

DRUG: Kineret

Sponsor

Federal Research Institute of Pediatric Hematology, Oncology and Immunology